Surgical IIH Treatment Trial
IIH 手术治疗试验
基本信息
- 批准号:9518911
- 负责人:
- 金额:$ 450.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcetazolamideAddressAffectAmericanBasement membraneBiomechanicsBiometryBlindnessCerebrospinal Fluid PressureCerebrospinal fluid shunts procedureClinical Trials DesignComplicationDataDevelopmentDietDiseaseDoseEnrollmentEpidemicEpithelialEvidence based treatmentEyeFemale of child bearing ageGanglion Cell LayerGoalsHealthcareImageIncidenceIndividualInstitutionIntentionInterventionIntracranial HypertensionIntracranial PressureInvestigationLeadershipMasksMeasuresMedicalMethodsNerve FibersNerve SheathsNewly DiagnosedObesityOperative Surgical ProceduresOphthalmologyOptic DiskOptic NerveOptical Coherence TomographyOutcomeOverweightPapilledemaPatientsPerimetryPlacebosPredictive ValueProbabilityPseudotumor CerebriQualifyingQuality of lifeRandomizedReadingRegimenResearchResearch DesignResearch InfrastructureResearch PersonnelResourcesRetinaRetinalRetinal Ganglion CellsRetinal PigmentsSiteTestingThickThinnessTimeTreatment FailureTreatment outcomeVisionVisitVisualVisual FieldsWeight maintenance regimenWomancomparative efficacyevidence baseexperiencefiber cellhigh riskimprovedplacebo controlled studypressurepreventprimary outcomeprogramsprospectivesecondary outcomesuccesstreatment grouptreatment strategytreatment trialyoung woman
项目摘要
PROJECT SUMMARY / ABSTRACT
Idiopathic intracranial hypertension (IIH) is a disorder of obese young women characterized by elevated
intracranial pressure (ICP) of unknown cause. It affects at least 100,000 Americans and its incidence is
increasing with the obesity epidemic. Because of pressure on the optic nerve (papilledema) about 10%
develop blinding visual loss.
We recently completed the Idiopathic Intracranial Hypertension Treatment Trial, a multicenter randomized,
double-masked, placebo-controlled study of 165 subjects with IIH and mild visual loss. We showed that
acetazolamide-plus diet was significantly superior to placebo-plus-diet for improving 1) perimetric mean
deviation (PMD, a global measure of visual field loss), 2) papilledema grade, 3) quality of life (QoL) measures
and ICP. Further, high dose acetazolamide (up to 4gm/day) was well tolerated. However, in subjects with
moderate to severe visual loss, no intervention, neither medical nor the various surgical approaches, has been
verified as efficacious by well-designed clinical trials.
We will enroll 180 newly diagnosed IIH subjects with a PMD between -8.5 and -30 dB in at least one eye, as
determined by automated perimetry. We will compare the efficacy of 1) maximal medical therapy (MMT), 2)
surgical intervention with optic nerve sheath fenestration + MMT, and 3) surgical intervention with intracranial
shunting + MMT using an intention-to-treat analysis. The primary outcome will be the change in PMD from
baseline to 6 months in the eye with the best qualifying PMD. Secondary outcomes include: OCT measures;
changes in papilledema grade, ICP; and QoL scores. We will investigate how interventions that purportedly
lower ICP determine a) biomechanical changes of the optic nerve head and b) if retina ganglion cell layer
thinning at baseline is associated with a poor visual outcome. We will follow subjects for at least two years to
determine the long-term outcomes of these treatment strategies.
The Neuro-ophthalmology Research Investigator Consortium (NORDIC) will provide the infrastructure and
experienced leadership to conduct the proposed study, consisting of 41 sites, the Data Coordination and
Biostatistics Center, three Reading Centers (under a Resource Center), and an Enrollment Center.
项目总结/摘要
特发性颅内高压(IIH)是一种肥胖年轻女性的疾病,其特征是颅内压升高,
颅内压(ICP)不明原因。它影响了至少10万美国人,其发病率是
随着肥胖症的流行而增加。由于视神经受压(视乳头水肿)约占10%
会导致失明
我们最近完成了特发性颅内高压治疗试验,一项多中心随机,
双盲、安慰剂对照研究,165例IIH和轻度视力丧失受试者。我们发现
乙酰唑胺+饮食显著上级安慰剂+饮食改善1)周长平均值
偏差(PMD,视野损失的整体测量),2)视乳头水肿等级,3)生活质量(QoL)测量
和ICP。此外,高剂量乙酰唑胺(高达4gm/天)耐受性良好。然而,在具有
中度至重度视力丧失,没有干预,无论是医疗还是各种手术方法,
经过精心设计的临床试验验证有效。
我们将入组180名新诊断的IIH受试者,至少一只眼睛的PMD在-8.5和-30 dB之间,
通过自动视野检查确定。我们将比较1)最大药物治疗(MMT),2)
视神经鞘开窗+ MMT的手术干预,和3)颅内
分流+ MMT使用意向治疗分析。主要结果将是PMD从
基线至6个月,具有最佳合格PMD。次要结局包括:OCT测量;
视神经乳头水肿等级、ICP和QoL评分的变化。我们将调查据称是
较低的ICP确定a)视神经乳头的生物力学变化和B)视网膜神经节细胞层
基线变薄与较差的视觉结果相关。我们将跟踪研究对象至少两年,
确定这些治疗策略的长期结果。
神经眼科研究者联盟(NORDIC)将提供基础设施,
由41个研究中心、数据协调和
生物统计中心,三个阅读中心(在资源中心下),和一个注册中心。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark J Kupersmith其他文献
Mark J Kupersmith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark J Kupersmith', 18)}}的其他基金
Statistical Unsupervised Learning VF for IIHTT & ONTT
IIHTT 的统计无监督学习 VF
- 批准号:
10436319 - 财政年份:2021
- 资助金额:
$ 450.57万 - 项目类别:
Statistical Unsupervised Learning VF for IIHTT & ONTT
IIHTT 的统计无监督学习 VF
- 批准号:
10192112 - 财政年份:2021
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
8531524 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
7314781 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
7766207 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
7883764 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
7930988 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
8926490 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network
神经眼科研究疾病研究者联盟 (NORDIC) 网络
- 批准号:
8238355 - 财政年份:2009
- 资助金额:
$ 450.57万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 450.57万 - 项目类别:
Research Grant